France is currently home to a very limited medical cannabis program that only serves a small fraction of the nation’s suffering patients, according to a report that was released today by Augur Associates and leading French cannabis media outlet Newsweed. The report, titled “State of the Medical Cannabis Industry in France – 2025“, determined that France’s permitted medical use of certain pharmaceutical cannabis products, combined with the nation’s medical cannabis pilot program, has resulted in safe access for only a microfraction of what a modernized medical cannabis program would provide.
